DocGo Inc
NASDAQ:DCGO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.8014
5.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
DocGo Inc
DocGo, Inc. operates as an emerging growth company, which provides mobile health services. The company is headquartered in New York City, New York. The company went IPO on 2020-10-15. The firm uses dispatch and communication technology to provide healthcare transportation and mobile services in-person medical treatment directly to patients in their homes, workplaces and other non-traditional locations, in various metropolitan cities in the United States and the United Kingdom. The company operates through two segments: medical mobility solutions and mobile health solutions. The Company’s medical mobility solutions are offered under the Ambulnz brand. The company enables access to local clinical services, including primary and specialty care, dialysis treatments for chronic care management, and transfers between clinical settings. The Company’s mobile health solutions include services performed at home and offices, coronavirus disease (COVID-19) testing, and event services, which include on-site healthcare support at sporting events and concerts.
DocGo, Inc. operates as an emerging growth company, which provides mobile health services. The company is headquartered in New York City, New York. The company went IPO on 2020-10-15. The firm uses dispatch and communication technology to provide healthcare transportation and mobile services in-person medical treatment directly to patients in their homes, workplaces and other non-traditional locations, in various metropolitan cities in the United States and the United Kingdom. The company operates through two segments: medical mobility solutions and mobile health solutions. The Company’s medical mobility solutions are offered under the Ambulnz brand. The company enables access to local clinical services, including primary and specialty care, dialysis treatments for chronic care management, and transfers between clinical settings. The Company’s mobile health solutions include services performed at home and offices, coronavirus disease (COVID-19) testing, and event services, which include on-site healthcare support at sporting events and concerts.
Revenue Drop: Total Q3 2025 revenue was $70.8 million, down from $138.7 million last year, entirely due to the end of migrant-related projects.
Base Business Growth: Excluding migrant programs, revenue grew 8% year-over-year, with strong volumes across core service lines.
Profitability Update: Q3 2025 adjusted EBITDA was a loss of $7.1 million versus a $17.9 million profit last year; most business lines are contribution-positive except Care Gap Closure and Primary Care.
2026 Guidance: DocGo expects $280–300 million in 2026 revenue (12–20% growth on base business), with an adjusted EBITDA loss of $15–25 million, improving throughout the year.
SteadyMD Acquisition: Recently acquired SteadyMD, adding a 50-state virtual care network and projecting $25 million in incremental 2026 revenue.
Strong Balance Sheet: Ended Q3 with $95.2 million in cash and no debt, expecting to exit 2026 with at least $65 million in cash.
Shift in Revenue Mix: Migrant-related revenue is expected to be zero in 2026; medical transportation and remote patient monitoring are highlighted as high-growth, profitable lines.
